Claudia Carbonari
Child & Adolescent Psychiatry · Glastonbury, CTNPI 1235357674
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.8% of the total across 142 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 23.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $3,052 and has fallen 72.5% since, to $838 in 2025. Among child & adolescent psychiatry clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 142 payments — averaging $82.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$3K
- AbbVie$2K
- Neuronetics, Inc.$2K
- Teva Pharmaceuticals USA, Inc.$927
- Neurocrine Biosciences, Inc.$891
- Alkermes, Inc.$858
- plus $3K from 12 others
What the payments were for
- Travel & lodging$1,0769%
- Food & beverage$10,64091%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 42 | $2,738 |
| AbbVie(2 entities) | 25 | $1,594 |
| Neuronetics, Inc. | 2 | $1,526 |
| Teva Pharmaceuticals USA, Inc. | 8 | $927 |
| Neurocrine Biosciences, Inc. | 9 | $891 |
| Alkermes, Inc. | 8 | $858 |
| Axsome Therapeutics, Inc. | 6 | $664 |
| Jazz Pharmaceuticals Inc. | 4 | $478 |
| Lundbeck LLC | 20 | $463 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $393 |
| Sunovion Pharmaceuticals Inc. | 3 | $361 |
| Johnson & Johnson | 1 | $123 |
| Corium, LLC | 1 | $122 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $120 |
| E.r. Squibb & Sons, L.L.C. | 1 | $119 |
| Ironshore Pharmaceuticals Inc. | 6 | $119 |
| Boehringer Ingelheim | 1 | $115 |
| Eisai Inc. | 1 | $106 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$2,666
- NEUROSTAR TMS THERAPY SYSTEM$1,526
- REXULTI$1,316
- VRAYLAR$956
- AUSTEDO$718
- INGREZZA$690
- ABILIFY MAINTENA$607
- SUNOSI$603
- Auvelity$486
- CAPLYTA$393
- ABILIFY ASIMTUFII$371
- LATUDA$361
- UBRELVY$234
- SPRAVATO$123
- Austedo XR$122
- Azstarys$122
- COBENFY$119
- Dayvigo$106
How this compares
$11,716 in reported general payments places this provider in the 95th percentile of 71 child & adolescent psychiatry providers in Connecticut.
See all child & adolescent psychiatry providers in Connecticut →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Escitalopram Oxalate | 14 | $17 |
Paid to pharmacies, not to this prescriber.
Other child & adolescent psychiatry in Glastonbury
- Milind KaleGlastonbury$310
- Steven SpectorPlantsville$278K
- Daniel KelleherDanbury$10K
- Cornelia GalloWestport$7K
- Allan JacobsWest Hartford$5K
- Robert KhalilDanbury$4K
- Aura ArdonDanbury$3K
- Ammar TraboulsiNew London$3K
- Mirjana DomakondaHartford$3K
- Tamar HanflingDanbury$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.